We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Euroimmun and Xpedite Diagnostics Partner to Offer Faster, Easier Protocols for DNA Extraction at POC

By LabMedica International staff writers
Posted on 19 Dec 2023
Print article
Image: Current users of EUROArray diagnostic platform will be offered EUROArray SwiftX-traction Kit for rapid manual DNA extraction (Photo courtesy of EUROIMMUN)
Image: Current users of EUROArray diagnostic platform will be offered EUROArray SwiftX-traction Kit for rapid manual DNA extraction (Photo courtesy of EUROIMMUN)

EUROIMMUN (Lübeck, Germany) and Xpedite Diagnostics (Hallbergmoos, Germany) have entered into a strategic partnership for offering faster and easier protocols for DNA extraction at the point-of-care. Current users of the EUROArray diagnostic platform will now have access to the EUROArray SwiftX-traction Kit designed for rapid manual DNA extraction. EUROArray SwiftX-traction significantly reduces the complexity as well as processing time of the DNA extraction. It can extract DNA from different challenging sample types using just a few steps that take less than 30 minutes.

The new extraction method is currently being validated in combination with various CE-marked EUROArray products. Xpedite Diagnostics aims to soon register the extraction kit itself as a CE-IVD device under the European IVD Regulation 2017/746. Xpedite Diagnostics’ partnership with EUROIMMUN demonstrates its technical leadership in offering high-performing and user-friendly nucleic acid extraction solutions. This, combined with its strong expertise in quality management and regulatory affairs, makes Xpedite Diagnostics well-positioned to act as a reliable and efficient contract developer as well as manufacturer for other IVD companies.

“EUROArray SwiftX-traction was tailored specifically to the needs of users of the EUROArray diagnostic platform and is based on our SwiftX Toolbox,” said Dr. Andy Wende, CEO and Head of R&D at Xpedite Diagnostics GmbH. “The development was finished in only a few months and will result in a CE-IVD marked DNA extraction kit. It merges several advantages such as high sensitivity, short workflows, and improved usability. EUROArray SwiftX-traction will enhance customer satisfaction and acceptance, ultimately leading to a better sales position of the EUROArray diagnostic platform in the segments Dermatomycosis, STI testing, and HPV typing.”

Related Links:
EUROIMMUN 
Xpedite Diagnostics 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.